Scott Tagawa, Md, On The Impact Of Racial Disparity And Covid-19 On Prostate Cancer Clinical Trials

Scott Tagawa, MD, on the Impact of Racial Disparity and COVID-19 on Prostate Cancer Clinical Trials

Impact of COVID-19 on the Prostate Cancer Racial Disparity Summit Session 1

Prostate Health Education Network

Scott Tagawa, MD, on the Prostate Cancer Treatment Pipeline

Scott Tagawa, MD, on PSMA Targeting in Prostate Cancer Treatment

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in mPC patients

Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter

Scott Tagawa, M.D. on PSMA PET-CT and its Utility in Prostate Cancer - Part 2

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

Scott Tagawa, M.D. on PSMA PET-CT and its Utility in Prostate Cancer - Part 1

Scott Tagawa, M.D., M.S.

Weill Cornell Genitourinary (GU) Cancer Program

Dr. Tagawa on BRCA2 in Patients with Prostate Cancer Receiving PSMA-Targeted Radionuclide Therapy

Racial disparities in prostate cancer clinical trial participation and survival outcomes

Dr. Tagawa Discusses Agents Targeted Against PSMA

Targeted Oncology

Is there a Biological Basis for Racial Disparities in Prostate Cancer? A Precision Policy Panel

Prostate Cancer Foundation

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

Dr. Tagawa on CTC in Neuroendocrine-Positive Prostate Cancer

Dr. Tagawa on Targeting PSMA in Prostate Cancer

Scott Tagawa, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive NMIBC